Clinical Trials Logo
  1. Home
  2. Myasthenia Gravis, Generalized
  3. NCT02473952

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized Clinical Trial

Official title:
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis

Clinical Trial Summary

The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.

Clinical Trial Description

The primary objective is to evaluate the efficacy of IGIV-C in subjects with generalized myasthenia gravis (MG) on standard of care treatment at study entry in terms of improvement in MG symptoms as measured by the mean change in Quantitative Myasthenia Gravis (QMG) score from Baseline (Week 0) to Week 24 as compared to placebo.

The safety objective of this study is to evaluate the safety and tolerability of IGIV-C loading dose of 2 g/kg followed by 7 maintenance dosages of 1 g/kg every 3 weeks through Week 21 in subjects with MG. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02473952
Study type Interventional
Source Grifols Therapeutics LLC
Contact
Status Completed
Phase Phase 2
Start date August 2015
Completion date January 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02565576 - Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis Phase 2
Completed NCT04115293 - Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Phase 3
Recruiting NCT05737160 - Study of Telitacicept in Generalized Myasthenia Gravis Phase 3
Recruiting NCT04224506 - A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
Recruiting NCT04431895 - Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study Early Phase 1
Recruiting NCT05067348 - Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis Phase 2
Withdrawn NCT03165435 - A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis Phase 2/Phase 3
Recruiting NCT05214612 - Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Recruiting NCT05868837 - Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) Phase 3
Recruiting NCT06282159 - A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Phase 2
Recruiting NCT04146051 - Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) Phase 2
Completed NCT03759366 - A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) Phase 3
Completed NCT00683969 - A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Phase 3
Completed NCT03304054 - Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Phase 3
Recruiting NCT05716035 - Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis Phase 2/Phase 3